Financial details of the acquisition were not disclosed, however Optimal’s 2022 revenue is expected to be approximately £7.5 million.
Optimal focuses on the automation and optimisation of batch and continuous processes in the biopharma industry – from R&D to manufacturing. It has more than 30 years of experience in delivering regulatory-compliant biopharma solutions, ranging from the development of automated control systems for process control to the award-winning, vendor-agnostic PAT knowledge management software synTQ.
Martin Gadsby, CEO and Co-Founder of Optimal Industrial Automation and Technologies, said: “We are delighted to become part of the Bruker family. Optimal and Bruker together are a perfect fit – we share the common ethos of innovation with integrity, together with our industry recognition as a high-quality solutions provider delivering tangible benefits to our customers.”
Dr Falko Busse, President of the Bruker BioSpin Group, added: “The acquisition of Optimal is a very exciting step for Bruker as it supports more comprehensive solutions for the biopharmaceutical industry, now adding the capabilities to integrate cutting-edge systems into biopharma manufacturing processes and workflows. We welcome the Optimal team with their strong PAT and automation expertise and, together, are eager to support biotech and pharmaceutical companies in increasing their manufacturing efficiency and flexibility – a global need highlighted by the response to the pandemic crisis.